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Nonvariceal  upper  gastrointestinal  bleeding  (NVUGIB)  con-
tinues  to  be  a  diagnostic  and  therapeutic  challenge.  Annual
NVUGIB  incidence  is  estimated  at  approximately  100  cases
per  100,000  inhabitants  and  the  mortality  rates  range  from
6%  to  15%.1 Despite  the  advances  in  NVUGIB  management,
particularly  in  endoscopic  technology,  there  has  been  no
signiﬁcant  decrease  in  mortality  in  this  group  of  patients.
On  the  other  hand,  serum  albumin  levels  have  been
shown  to  have  predictive  capacity  for  morbidity  and  mor-
tality  in  different  clinical  scenarios,  from  elective  and
emergency  surgeries  to  cerebrovascular  events.
In  this  issue  of  the  Revista  Mexicana  de  Gastroen-
terología,  González-González  et  al.2 describe  how  low  levels
of  serum  albumin  are  associated  with  a  higher  mortality
rate  in  patients  with  NVUGIB.  They  deﬁned  hypoalbumine-
mia  as  levels  <  3.5  g/dl  and  it  was  present  in  more  than
70%  of  the  NVUGIB  patients  evaluated  over  a  4-year  period.
Levels  <  3.2  g/dl  had  an  appropriate  predictive  capacity  for
mortality  (area  under  the  curve  [AUC]:  0.74),  slightly  better
than  the  Rockall  index  (AUC:  0.72).  Furthermore,  the  mor-
tality  rate  was  11%  in  the  patients  with  albumin  <  3.2  g/dl,
compared  with  only  1%  in  the  patients  with  albumin  ≥
3.2  g/dl  (p  =  0.009;  odds  ratio:  9.7).  As  was  expected,  the
group  of  patients  between  the  sixth  and  seventh  decades
of  life,  an  independent  risk  factor  for  mortality  in  NVUGIB,
was  the  most  affected  in  relation  to  comorbidities.  Like-
wise,  a  signiﬁcantly  higher  percentage  of  hypoalbuminemia
was  detected  in  that  age  group.
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redictive  factor  for  mortality  mainly  in  patients  with  gas-
rointestinal  bleeding  associated  with  portal  hypertension.3
owever,  the  same  group  of  authors  previously  reported  on
 larger  cohort  that  included  patients  with  liver  disease,
hronic  kidney  disease,  and  neoplasia.  In  that  study,  hypoal-
uminemia  was  also  an  independent  predictor  of  hospital
ortality  in  NVUGIB.4
In  conclusion,  serum  albumin  is  an  accessible  tool  that
nables  risk  stratiﬁcation  in  patients  with  NVUGIB.  The  asso-
iation  of  low  serum  albumin  levels  and  greater  mortality  in
VUGIB  could  be  due  to  the  greater  frequency  of  hypoalbu-
inemia  in  patients  with  malnutrition,  chronic  subclinical
iver  diseases  (e.g.  fatty  liver  disease),  or  chronic  diseases
ssociated  with  increased  catabolism  (e.g.  kidney  diseases,
iabetes,  cardiovascular  diseases).  Nevertheless,  this  asso-
iation  will  have  to  be  clariﬁed  in  future  studies.
Previous  studies  have  shown  how  medical  strategies
hat  are  easy  to  adopt,  such  as  restricting  blood  trans-
usion  in  patients  with  upper  gastrointestinal  bleeding
nd  hemoglobin  levels  <  70  mg/dl,  are  associated  with
etter  outcome,  compared  with  those  patients  that  receive
ransfusions  under  a  less  conﬁning  criterion  (<  90  mg/dl).5
herefore,  the  results  of  the  present  study  should  stimulate
he  performance  of  controlled  clinical  trials  on  albumin
nfusions  in  NVUGIB  patients,  mainly  in  those  with  hypoal-
uminemia,  for  the  purpose  of  improving  outcome  in  these
atients.
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